43 related articles for article (PubMed ID: 18660730)
1. Controlled-release carvedilol in the treatment of essential hypertension.
Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
3. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
Bakris GL; Tarka EA; Waterhouse B; Goulding MR; Madan A; Anderson KM; St John Sutton M; Miller AB; Reichek N
Am J Cardiol; 2006 Oct; 98(7A):46L-52L. PubMed ID: 17023232
[TBL] [Abstract][Full Text] [Related]
5. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
6. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
Bakris GL; Weber MA
Rev Cardiovasc Med; 2008; 9(2):96-105. PubMed ID: 18660730
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
Fardoun RZ
Pharmacotherapy; 2006 Oct; 26(10):1491-500. PubMed ID: 16999659
[TBL] [Abstract][Full Text] [Related]
8. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
9. Role of carvedilol controlled-release in cardiovascular disease.
Fonarow GC
Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
[TBL] [Abstract][Full Text] [Related]
10. beta-Blockers in hypertension: is carvedilol different?
Messerli FH; Grossman E
Am J Cardiol; 2004 May; 93(9A):7B-12B. PubMed ID: 15144930
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
DiNicolantonio JJ; Hackam DG
Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):13-25. PubMed ID: 22149523
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol in hypertension treatment.
Stafylas PC; Sarafidis PA
Vasc Health Risk Manag; 2008; 4(1):23-30. PubMed ID: 18629377
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
